Together with arterial hypertension and diabetes mellitus, lipid metabolism disorders are among the most important modifiable cardiovascular risk factors. In addition to statins, various modern substance classes are now available for lowering LDL-C levels with medication. Through an adapted step therapy, the respective target values can be achieved in many patients, also in secondary prevention after acute coronary syndrome (ACS).
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Pathophysiological mechanisms and therapeutic perspectives
Metabolic syndrome in patients with schizophrenia
- Hand eczema: from diagnosis to treatment
Implementing sustainable, stage-appropriate measures
- Cystic fibrosis
Small spray – big footprint
- From symptom to diagnosis
Abdominal pain – Gastric outlet stenosis
- When the bones become more fragile: “Case Finding”
Fracture risk reduction in osteoporosis
- Biologics for plaque psoriasis
What increases the chance of a sustained remission?
- Findings from the ALS Symposium 2024 in Montreal
Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)
- Pain and autism